Interferon preparation in complex therapy of virus-associated genital diseases in women

Background. The high incidence of virus-induced genital tract infections in women, with a high recurrence rate and associated reproductive problems, prompted a review analysis of studies examining the antiviral and immunomodulatory effects of interferon alpha-2b with antioxidants in combination therapy for patients with genital virus-associated infections to optimize therapy during the preconception phase.

Objective. To evaluate the clinical efficacy of the antiviral immunomodulatory drug, administered as rectal suppositories, in the combination treatment of virus-associated genital tract infections in women based on data from a review analysis of studies.

Materials and methods. A selection of relevant publications on the development, antiviral, and immunomodulatory effects of interferons and interferon alpha-2b with antioxidants in vivo and in vitro was conducted in the scientific citation databases PubMed and Google Scholar. A cumulative analysis of the results of using the antiviral immunomodulatory drug in the combination treatment of patients with genital herpes and diseases associated with the human papillomavirus (HPV) was performed.

Results. A cumulative analysis of the results of using interferon-alpha-2b with antioxidants in the treatment of virus-associated diseases involved 5,900 patients aged 14 to 52 years. The antiviral and immunomodulatory effects and high clinical efficacy of interferon alpha-2b with antioxidants as rectal suppositories in the combination treatment of HPV-associated and herpesvirus diseases of the genital tract were demonstrated, with a reduction in the severity of lesions, a decrease in the recurrence rate, and an increase in the successful pregnancy rate. Conclusion. The obtained results dictate the need to include interferon alpha-2b with antioxidants in the form of rectal suppositories 1,000,000 IU No. 10 in the combination therapy of genital herpesvirus and HPV-associated diseases during the pre-pregnancy stage to prevent virus-associated diseases during gestation and improve reproductive outcomes.

1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2021. https://files.medelement.com/uploads/materials/99750200317e4a43834398fad1bbd0be.pdf (23. jule 2021).

2. Kombe Kombe A. J., Li B., Zahid A., et al. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front. Public Health. 2021; 8: 552028. DOI: 10.3389/fpubh.2020.552028.

3. Into the archives: the story of HPV and cervical cancer. Cancer research center. URL: https://news.cancerresearchuk.org/2022/11/21/into-the-archives-thestory-of-hpv-and-cervical-cancer/.

4. Kubanov A. A., Bogdanova E. V. The performance of the healthcare organisations providing dermatovenereology care, 2019-2021, Russian Federation. Vestnik dermatologii i venerologii. 2022; 98 (5): 18-33. (In Russ.)

5. Johnston C., Corey L. Current concepts for genital herpes simplex virus infection: diagnostics and pathogenesis of genital tract shedding. Clin. Microbiol. Rew. 2016; 29 (1): 149-161. DOI: 10.1128/CMR.00043-15.

6. Herpes genitalis in the clinical practice of a dermatovenereologist and an Obstetrician-Gynecologist: Interdisciplinary Interaction Issues. Voprosy practicheskoy kolposkopii. Genitalnye infectsii. 2022; (2): 37-42. (In Russ.)

7. Dobrokhotova Yu. E., Kononova I. N., Kareva E. N. Infections in Obstetrics and Gynecology: Textbook. Ed. Dobrokhotova Yu. E. M.: KNORUS, 2024. 304 c. (In Russ.)

8. Aggerholm B. S., Ostenfeld E. B., Andersen L. H. J., Krogh R. H. A., et al. Herpes genitalis under graviditetogfodsel. 2020; 182: V09190527.

9. Tramontano L., Sciorio R., Bellaminutti S., Esteves S. C., et al. Exploring the potential impact of human papillomavirus on infertility and assisted reproductive technology outcomes. Reprod. Biol. 2023; 23 (2): 100753. DOI: 10.1016/j.repbio.2023.100753.

10. Gabidullina R. I., Egamberdieva L. D., Aslan G. S., Pokrovskaya Yu. S. The impact of Human Papillomavirus on fertility and on the outcomes of Assisted Reproductive Technology programs. Zhenskoye zdorove i reproductsiya. 2024; 2 (63). DOI: 10.31550/2712-8598-2024-26-ZhZiR. (In Russ.)

11. Rocha R. M., Souza R. P., Gimenes F., Consolaro M. E. L. The high-risk human papillomavirus continuum along the female reproductive tract and its relationship to infertility and endometriosis. Reprod. Biomed. Online. 2019; 38 (6): 926-937. DOI: 10.1016/j.rbmo.2018.11.032.

12. Sadykova D. A., Zefirova T. P., Mingulova Z. M. Human Papillomavirus infection and women’s reproductive health. Practicheskaya meditsina. 2025; 2 (23). (In Russ.)

13. Zefirova T. P., Tolibova G. Kh., Sadykova D. A., et al. A new outlook on the reasons of the reproductive issues in women with chronic endometritis. Akusherstvo i ginekologiya. 2024; 9: 156-162. DOI: 10.18565/aig.2024.237. (In Russ.)

14. Respiratory medicine: guide: Vol. 1-4 / Ed. A. G. Chuchalin. 3rd Ed., ed. and rev. M.: PulmoMedia, 2024. Vol. 1, pp. 1-668: illus. https://doi.org/10.18093/987-5-6048754-9-0-2024-1-242-248. (In Russ.)

15. Happel A. U., Varsani A., Balle C., Passmore J. A., Jaspan H. The vaginal virome-balancing female genital tract bacteriome, mucosal immunity, and sexual and reproductive health outcomes? Viruses. 2020; 12 (8): E832. https://dx.doi.org/10.3390/v12080832.

16. Grigorieva O. Yu. The role of TLR9 in antiherpetic immunity. The influence of science on the innovative development. 2017; 2: 7-9. (In Russ.)

17. Pietras E. M., Saha S. K., Cheng G. The interferon response to bacterial and viral infections. J. EndotoxinRes. 2006; 12 (4): 246-250.

18. Markelova E. V., Tulupova M. S., Nevezhkina T. A., Matushkina L. S., Chernikova M. A., Knysh S. V. Interferon profile of the mucosal immunity in women with human papillomavirus infection. Rossiiskii meditsinskii zhurnal. Meditsinskoye obozreniye. 2022; 6 (2): 67-71. DOI: 10.32364/2587-6821-2022-6-2-67-71. (In Russ.)

19. Kononova I. N., Kareva E. N., Dobrokhotova Yu. E., et al. The significance of Hexapeptide in the complex therapy in women with infertility in the context of chronic endometritis. Effectivnaya farmakoterapiya. 2025; 21 (38): 30-36. (In Russ.)

20. Shmakova N. A., Chistyakova G. N., Kononova I. N., Remizova I. I., et al. Highrisk Human Papillomavirus (HPV) related Cervical Intraepithelial Neoplasia and cervical cancer: the relevance of the issue, identifying prospects (literature review). Problemy reproductsii. 2021; 27 (1): 33-38. (In Russ.)

21. Bocharova I. I., Zarochentseva N. V., Vlasova V. A., Aksenov A. N., et al. The impact of maternal human papillomavirus infection on the health of a newborn. Rossiiskii vestnik akushera-ginekologa. 2020. 20 (4): 82-87. (In Russ.)

22. Clinical guidelines “Anogenital herpes simplex infection” - 2024-2025-2026 (09.07.2024) – Approved by the Ministry of Health of the Russian Federation, file:///C:/Users/Irina/Desktop/Новые%20КР%202024/Anogenitalny%20gerpes,%20КР%202024.pdf. (In Russ.)

23. Clinical guidelines "Cervical Intraepithelial Neoplasia, cervical erosion and cervical ectopy" – 2024-2025-2026 (25.09.2024) – Approved by the Ministry of Health of the Russian Federation, file:///C:/Users/Ирина/Desktop/Новые%20КР%202024/ЦИН,%20КР%202024.pdf. (In Russ.)

24. Jin L., and Chen T. The Effects of Secretory IgA in the Mucosal Immune System. Biomed Res Int. 2020; 2020: 2032057. DOI: 10.1155/2020/2032057.

25. The instruction for the use of Viferon. (In Russ.)

26. Loginova S. Ya., Schukina V. N., Savenko S. V., Borisevich S. V. In vitro activity of human recombinant interferon alfa-2b against SARS-CoV-2. Voprosy virusologii. 2021; 66 (2): 123-128. DOI: https://doi.org/10.36233/0507-4088-13. (In Russ.)

27. Clinical guidelines "Anogenital warts". 2020. URL: https://cr.minzdrav.gov.ru/schema/204_1. (In Russ.)

28. Costa-Silva M., Fernandes I., Rodrigues A. G., et al. Anogenital warts in pediatric population. An. Bras. Dermatol. 2017; 92 (5): 675-681. DOI: 10.1590/abd1806-4841.201756411.

29. Araújo M. G., Magalhães G. M., Garcia L. C., et al. Update on human papillomavirus — Part II: complementary diagnosis, treatment and prophylaxis. An. Bras. Dermatol. 2021; 96 (2): 125-318. DOI: 10.1016/j.abd.2020.11.005.

30. Ritzmann F., Lunding L. P., Bals R., et al. IL-17 Cytokines and Chronic Lung Diseases. Cells. 2022; 11 (14). DOI: 10.3390/cells11142132.

31. Gizinger O. A. Clinical and laboratory substantiation and effectiveness evaluation of recombinant interferon alfa-2b in genital herpes therapy. Infectsionnye bolezni. 2021; 19 (3): 58-66. DOI: 10.20953/1729-9225-2021-3- 58-66. (In Russ.)

32. Zarochentseva N. V., Belaya Yu. M., Malinovskaya V. V. Modern opportunities of the anogenital warts treatment in girls and young women. Akusherstvo i ginekologiya: novosti, mneniya, obucheniye. 2017; 2: 37-42. DOI: 10.24411/2303-9698-2017-00029. (In Russ.)

33. Bairamova G. R., Baranov I. I., Dobrovolskaya D. A., Pronina V. A., Andreev A. O., Malinovskaya V. V., Shuvalov A. N. Anogenital warts: modern perspective on the issue. Doctor.Ru. 2021; 20 (8): 28-35. DOI: 10.31550/1727-2378-2021-20-8-28-35. (In Russ.)

34. Kravchenko E. N., Ulianova I. O., Filatova S. I., Kudymova T. N. The effectiveness of the complex treatment of anogenital warts in women including interferon alfa-2b with antioxidants. Voprosy ginekologii, akusherstva i perinatologii. 2025; 24 (1): 164-171. DOI: 10.20953/1726-1678-2025-1-164-171. (In Russ.)

35. Nesterova I. V., Kovaleva S. V., Chudilova G. A., et al. The positive effect of the integration program of the pre-conception care of immune system in women with infectious inflammatory diseases of the genital tract. Effectivnaya farmakoterapiya. 2022; 18 (12): 20-27. (In Russ.)

36. Kononova I. N., Kosovtsova N. V., Kareva E. N., Pospelova Ya. Yu. Interferon therapy in the complex treatment of vulvovaginitis in patients with multiple pregnancy. Voprosy ginekologii, akusherstva i perinatologii. 2019; 18 (1): 46-52. DOI: 10.20953/1726-167.2019-1-46-52. (In Russ.)

37. Zarochentseva N. V., Belaya Yu. M., Samsygina G. A., et al. Human papillomavirus infection and HPV-associated diseases. Lechaschi Vrach. 2017; 4: 56. (In Russ.)

38. Kagramanova Zh. A., Lanschakova P. E., Malinovskaya V. V., Svistunov A. A., Vyzhlova E. N., Paramonova N. B. Clinical-morphological monitoring and obstetric ultrasound of missed miscarriage. The justification of personalized treatment. Voprosy ginekologii, akusherstva i perinatologii. 2019; 18 (3): 35-45. DOI: 10.20953/1726-1678-2019-3-35-45. (In Russ.)

39. Abukhaltam Akhmad D. A., Polesko I. V., Khaldin A. A., Kim D. G. Improving the therapy of latent forms of HPV infection. Klinicheskaya dermatologiya i venerologiya. 2024; 23 (5): 575-580. https://doi.org/10.17116/klinderma202423051575. (In Russ.)

40. Tapilskaya N. I., Shakhova M. A. Preconception care for couples for frequent recurrent bacterial vaginosis. Lechaschi Vrach; 2018; 2. (In Russ.)

41. Kosenkova T. V., Zazerskaya I. E., Klikunova K. A. in pregnant women and the intrauterine exposure of newborns to recombinant interferon alpha-2b: findings of a meta-analysis. Voprosy ginekologii, akusherstva i perinatologii. 2020; 19 (4): 110-136. DOI: 10.20953/1726-1678-2020-4-110-136. (In Russ.)

42. Ovchinnikova M. A., Santalova G. V., Lipatov I. S., Tezikov Yu. V. Shaping of the health of infants in the first half-year of life through preventive therapy for women with recurrent herpesvirus infection. Detskiye infectsii. 2018; 17 (1): 45-49. DOI: http://dx.doi.org/10.22627/2072-8107-2018-17-1-45-49. (In Russ.)